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ABSTRACT
The therapeutic potential of the highly active anticancer agent
cisplatin is severely limited by the occurrence of cellular resis-
tance. A better understanding of the molecular pathways in-
volved in cisplatin-induced cell death could potentially indicate
ways to overcome cellular unresponsiveness to the drug and
thus lead to better treatment results. We used the budding
yeast Saccharomyces cerevisiae as a model organism to iden-
tify and characterize novel genes involved in cisplatin-induced
cell kill, and found that SKY1 (SR-protein-specific kinase from
budding yeast) is a cisplatin sensitivity gene whose disruption
conferred cisplatin resistance. In cross-resistance studies, we
observed resistance of yeast sky1 cells (i.e., cells from which
the SKY1 gene had been disrupted) to cisplatin, carboplatin
(but not oxaliplatin), doxorubicin and daunorubicin, and hyper-
sensitivity to cadmium chloride and 5-fluorouracil. Furthermore,
these cells did not display reduced platinum accumulation,
DNA platination or doxorubicin accumulation, indicating that
the resistance is unrelated to decreased drug import or in-
creased drug export. Based on the modification of the antican-
cer drug sensitivity profile and our finding that sky1 cells
display a mutator phenotype, we propose that Sky1p might
play a significant role in specific repair and/or tolerance path-
ways. Disruption of the S. cerevisiae SKY1 gene would thus
result in deregulation of such mechanisms and, consequently,
lead to altered drug sensitivity.
Intrinsic or acquired resistance to cisplatin is frequently
encountered and severely limits the therapeutic potential of
this drug, which is highly active against cancers of the lung,
ovary, bladder, head and neck, esophagus, cervix, and endo-
metrium, and curative for most patients with testicular can-
cer (Kelland, 1994; Einhorn, 1997). It is generally believed
that a better understanding of the pathways leading to cis-
platin-induced cell death might shed light on putative mech-
anisms operative in the cisplatin resistance phenotype.
Ample evidence indicates that cisplatin exerts its cytotoxic
action by the formation of platinum-DNA adducts. Although
less abundant lesions such as the interstrand cross-links do
play their parts, the predominant 1,2-intrastrand GpG and
ApG cross-links (which represent approximately 90% of the
total adducts) are generally thought to be the DNA lesions of
most therapeutic significance (Pratt et al., 1994; Johnson et
al., 1998). In vitro studies have revealed that the mecha-
nisms by which cells may overcome the cytotoxic action of
cisplatin include decreased intracellular drug accumulation,
inactivation by glutathione or metallothioneins (leading to
reduced DNA platination), aberrations in repair, enhanced
tolerance, and defects in pathways modulating cell death
(Perez, 1998).
Paradoxically, repair of cisplatin-induced DNA damage
has been implicated in both cisplatin resistance and sensi-
tivity. The nucleotide excision repair (NER) system effi-
ciently removes a broad spectrum of DNA lesions, including
those produced by UV radiation and cisplatin. Enhanced
NER playing a role in cisplatin resistance has been observed
frequently (Crul et al., 1997), and reduced NER might ac-
count for the hypersensitivity of testicular germ cell tumors
(Kelland, 1994). Whereas NER deficiency leads to cisplatin
hypersensitivity, mismatch repair (MMR) defects make cells
resistant to the drug (Crul et al., 1997; Vaisman et al., 1998).
Two prominent models have been proposed to explain the
latter phenomenon. First, binding of MMR proteins to cispla-
tin-DNA adducts might directly activate signal transduction
pathways leading to cell cycle arrest and/or cell death. Alter-
natively, futile cycles of translesion synthesis past DNA le-
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sions, followed by recognition and removal of the newly syn-
thesized strand by an active hMutS/hMutL MMR protein
complex, are thought to generate gaps or strand breaks that
induce cell death. It is believed, therefore, that loss of MMR
leads to increased replicative bypass of cisplatin adducts and
reduced cell death and, thus, resistance (Crul et al., 1997;
Vaisman et al., 1998).
Currently known in vitro mechanisms of cisplatin resis-
tance do not fully account for the observed in vivo unrespon-
siveness of particular tumors to platinum-based chemother-
apy (Perez, 1998). Hence, additional cisplatin resistance
mechanisms, for which the genes involved still have to be
identified, are believed to exist.
We are using the budding yeast Saccharomyces cerevisiae
as a model system to study modulation of drug sensitivity.
We have performed a genome-wide functional screen to iden-
tify and characterize novel cisplatin sensitivity genes, and
found that disruption of the S. cerevisiae SKY1 (SR-protein-
specific kinase from budding yeast) gene conferred cellular
resistance to cisplatin (Schenk et al., 2001). In the cross-
resistance studies presented here, we observed resistance of
yeast sky1 cells (i.e., cells from which the SKY1 gene had
been disrupted) to cisplatin, carboplatin (but not oxaliplatin),
doxorubicin, daunorubicin, and hypersensitivity to cadmium
chloride and 5-fluorouracil. Based on the cytotoxicity data
and our finding that sky1 cells show a mutator phenotype,
we propose that Sky1p might play a significant role in MMR,
base excision repair, and/or Rev3p-dependent pathways. Dis-
ruption of SKY1 would thus result in deregulation of repair
and/or tolerance mechanisms and, consequently, lead to al-
tered drug sensitivity.
Materials and Methods
Chemicals. Yeast Nitrogen Base and Yeast extract/Peptone/Dex-
trose Broth were purchased from DIFCO Laboratories (Detroit, MI).
Cisplatin [Platosin, cis-diamminedichloroplatinum(II)] and doxoru-
bicin hydrochloride (Doxorubin) were obtained from Pharmachemie
(Haarlem, The Netherlands), carboplatin [Paraplatin, cis-diam-
mine(1,1-cyclobutanedicarboxylato)platinum(II)] and etoposide (Ve-
pesid) were from Bristol-Myers Squibb (Woerden, The Netherlands),
and oxaliplatin [Eloxatin, [trans-(L)-1,2-diaminocyclohexane]oxala-
toplatinum(II)] was from Sanofi-Synthelabo (Maassluis, The Neth-
erlands). Procarbazine hydrochloride (Natulan) was obtained from
Sigma-Tau Pharmaceuticals (Assen, The Netherlands). 6-Mercapto-
purine was purchased from BUFA Pharmaceutical Products (Uit-
geest, The Netherlands), and 5-fluorouracil (Fluorouracil-TEVA)
from TEVA Pharma (Mijdrecht, The Netherlands). Other chemicals
including cytotoxic agents and verapamil were obtained from Sigma-
Aldrich (Zwijndrecht, The Netherlands).
Yeast Strains and Growth Conditions. Saccharomyces cerevi-
siae strains used in this study were NER- and recombinational
repair-proficient W303-1B (MAT ho ade2–1 can1–100 his3–11,15
leu2–3,112 trp1–1 ura3–1), isogenic NER-deficient rad4 mutant
MGSC131 (rad4::hisG-URA3-hisG) (Verhage et al., 1996) and iso-
genic recombinational repair-deficient rad52 mutant MGSC194
(rad52::TRP1). Uracil-deficient strain MGSC283 was derived from
MGSC131 by selection on synthetic medium plates containing
5-fluoro-orotic acid (see below). Strain MGSC284 and MGSC186
were made by replacing the ura3 allele of MGSC283 and W303-1B,
respectively, with PCR-generated wild-type URA3 sequence. Yeast
strains were routinely grown on selective synthetic Yeast Nitrogen
Base medium at 30°C as described previously (Burger et al., 2000).
Although strain W303-1B is generally used as a wild-type yeast
background, it has been reported that there is a spontaneous G-to-A
transition change in the W303 RAD5 sequence, resulting in a weak
rad5–535 allele (Fan et al., 1996).
Isolation of Cisplatin-Resistant Yeast Strains. In a previous
study, we transformed cisplatin-sensitive S. cerevisiae strain
MGSC131 with a yeast genomic mini-Tn3::lacZ::LEU2 transposon
insertion library (Burns et al., 1994). The cisplatin-resistant pheno-
type of transposon-derived colonies surviving a one-step drug selec-
tion at 4 g/ml cisplatin was confirmed in semiquantitative and
quantitative cytotoxicity assays as described below. The sequences
flanking the single transposon elements were then identified by
inverse PCR and sequencing of the resulting PCR products employ-
ing transposon-specific primers, followed by comparison with public
databases (Schenk et al., 2001). S. cerevisiae MGSC-sky1 and
W303-sky1 cells containing a gene-specific SKY1 disruption were
generated by one-step gene replacement [i.e., transformation of
strain MGSC283 and W303-1B, respectively, with a knockout con-
struct obtained using primers SKY1–5A (5-gTA AgA AAg CTg ggA
Tgg ggC CAC TTC TCA TCT TTg ACA gCT TAT CAT C-3) and
SKY1–3 (5-Cgg AAC CAC TCC CgT ACA ACT CTC TAT CAg gTA
CCC ACT CgT gCA CCC-3)]. Successful gene disruption was con-
firmed by PCR and Northern blotting as described previously
(Schenk et al., 2001). RAD52 was disrupted from W303-1B-derived
sky1 cells by transformation of BamHI-linearized plasmid pSM21
as described previously (Siede et al., 1996). This yielded strain
rad52 sky1, for which successful disruption of the RAD52 gene
was confirmed by Southern blotting.
Construction of Expression Plasmids. A 2.3-kb SKY1 PCR
product was generated using primers SKYex-5 (5-ATA gTg gAT
CCT ggT ATA AAT AgA CAC CCC C-3) and SKYex-3 (5-CTA ACC
TCg AgA ggg CAA AAT AAA ggT ATA AAg g-3), and cloned into the
low-copy S. cerevisiae expression vector pYCTEF containing the con-
stitutive translation elongation factor 1 promoter (Schenk et al.,
2001). Alternatively, the SKY1 coding region was cloned into high-
copy 2-based yeast expression vector pEG202 (Gyuris et al., 1993)
harboring the constitutive alcohol dehydrogenase promoter. The
SKY1 insert for pEG202 was made by PCR using primers SKY-ATG
(5-CAT ggA TCC ATA Tgg gTT CAT CAA TTA ACT ATC C-3) and
SKYex-3.
Cytotoxicity Assays. Relative cisplatin or doxorubicin sensitiv-
ity was determined by a semiquantitative spot assay as described
previously (Burger et al., 2000). Alternatively, suspensions of cells
were streaked onto selective medium plates containing 0, 2, 3, 4, or
5 g/ml cisplatin and incubated at 30°C for 3 to 4 days. Sensitivity to
cytotoxic chemicals was quantitatively analyzed by a clonogenic sur-
vival assay. Serial dilutions of mid-log phase yeast cells were plated
onto selective medium containing various compound concentrations.
Upon incubation at 30°C for 3 to 4 days, colonies were counted and
percent survival was calculated based on the number of colonies
arising in the absence of cytotoxic chemical. Sensitivity to ionizing
radiation was tested by a similar assay, during which plating of the
yeast cells was immediately followed by irradiation with increasing
doses of  rays (0, 50, 100, 200, 400 and 500 Gy) using opposing 137Cs
sources (Gamma Cell 40; Atomic Energy of Canada, Ottawa, Can-
ada) at a rate of 1.06 to 1.08 Gy/min. Sensitivity to UV light was
tested by a semiquantitative spot assay as described previously
(Burger et al., 2000), using a germicidal lamp at 254 nm.
Determination of Intracellular Platinum Accumulation
and DNA Platination. Cellular platinum content was measured by
atomic absorption spectrometry (AAS) using a flameless spectrome-
ter (4110 ZL; PerkinElmer, Foster City, CA) as described previously
(Burger et al., 2000). Briefly, 2  107 exponentially growing yeast
cells were incubated in 5 ml of selective liquid medium containing
various concentrations of cisplatin (0, 5, 10, 20, and 40 g/ml) for
18 h and, after drug exposure, immediately washed three times. A
total of 4  107 cells were then pelleted and lysed in 100 l of
chloroform. After evaporation of residual chloroform, samples were
dissolved in 0.2% nitric acid and subjected to AAS to determine total
platinum content. DNA platination was measured by 32P-postlabel-
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ing. Briefly, 4  107 exponentially growing S. cerevisiae cells were
incubated in 10 ml of selective liquid medium containing various
concentrations of cisplatin (0, 5, and 40 g/ml) for 18 h. Genomic
DNA was then isolated and dissolved in 100 l of H2O, and GpG and
ApG adduct levels were determined as described previously (Pluim
et al., 1999).
Determination of Intracellular Doxorubicin Accumulation.
Cellular doxorubicin content was measured by high-performance
liquid chromatography (HPLC) as described previously (de Bruijn et
al., 1999). Briefly, 8  106 exponentially growing yeast cells were
incubated in 2 ml of selective liquid medium per Hemogard Vacu-
tainer tube (Becton Dickinson, Franklin Lakes, NJ) containing var-
ious concentrations of doxorubicin (0, 30, 60, 120, and 240 g/ml) for
18 h and, after drug exposure, immediately washed three times in
ice-cold medium. A total of 2 107 cells were then pelleted, dissolved
in drug-free human plasma, and subjected to pretreatment and
HPLC as described previously (de Bruijn et al., 1999) to determine
total doxorubicin content.
Determination of Mutation Rates. Spontaneous mutation
rates were established by monitoring conversion of the URA3 to the
ura3 mutant phenotype. For each strain tested, a total of 15 parallel
cultures were inoculated at  100 cells/ml and grown to stationary
phase in liquid Yeast extract/Peptone/Dextrose Broth at 30°C. The
viable titers and numbers of mutants were determined by plating
different aliquots of the cultures on the appropriate media. Muta-
tions in the URA3 locus leading to abrogation of gene function were
detected using synthetic medium plates containing 1 mg/ml 5-fluoro-
orotic acid as described previously (Boeke et al., 1984). Rates were
calculated from the resulting median mutant frequencies as de-
scribed previously (Drake, 1991).
Results
Isolation of Cisplatin-Resistant Yeast Strains. In or-
der to identify yeast genes that, upon disruption, confer cis-
platin resistance, we previously introduced a yeast genomic
transposon insertion library (Burns et al., 1994) into Saccha-
romyces cerevisiae cells (Schenk et al., 2001). Transformation
of yeast with this library corresponds to replacement of the
original yeast genomic copy with the mutagenized version, by
homologous recombination between yeast DNA transposon
flanking sequences and endogenous genomic sequences.
NER-deficient rad4 strain MGSC131 was used as recipient
because it is hypersensitive to cisplatin and, thus, displays a
steep dose-response curve to the drug (McA’Nulty and Lipp-
ard, 1996; Burger et al., 2000), enabling clear-cut selection of
cisplatin-resistant colonies at a relatively low drug dose.
When 3  105 library-derived transformants were screened
and subsequently retested for cisplatin resistance, nine
strains showing a 4-fold cisplatin resistance were selected for
further characterization. It turned out that the YMR216C
locus had been disrupted in at least five transposon-contain-
ing cisplatin-resistant yeast strains. From the different sizes
of the inverse PCR products, we inferred that at least three of
these strains had been derived from independent transfor-
mants (Schenk et al., 2001). In the remaining cisplatin-resis-
tant yeast strains, other loci turned out to be disrupted, as
will be described elsewhere (P. W. Schenk, M. Brok, A. W. M.
Boersma, J. A. Brandsma, H. den Dulk, H. Burger, G. Stoter,
J. Brouwer, K. Nooter, manuscript in preparation). The
YMR216C locus corresponds to the SKY1 (SR-protein–spe-
cific kinase from budding yeast) gene, which encodes a pro-
tein serine/threonine kinase with structural and functional
homology to the human SR-protein–specific kinases (SR-
PKs). The SR-protein–specific kinases and their substrates
(the serine/arginine-rich- or SR-proteins, including yeast
Npl3p) are thought to be key regulators of RNA processing
and, in mammalian cells, alternative splicing, through mul-
tiple mechanisms (Siebel et al., 1999; Yun and Fu, 2000).
Disruption of the SKY1 Gene Renders Yeast Cells
Cisplatin-Resistant. The cisplatin-resistant phenotype of
the transposon containing yeast strains in principle could
have arisen either from library-derived gene disruption or,
despite the low dose of cisplatin used for selection, from
cisplatin-induced mutations acquired during the screening
procedure. Therefore, we independently disrupted the SKY1
gene from the S. cerevisiae genome using PCR-generated
one-step gene replacement constructs, and determined the
cisplatin sensitivity profile of the resulting sky1 cells (Fig.
1A). Like transposon-derived sky1 transformants, MGSC-
sky1 cells generated by one-step gene replacement were
about 4-fold more cisplatin-resistant than MGSC131 SKY1
cells (Schenk et al., 2001).
To further confirm that cisplatin resistance was linked to
disruption of the SKY1 gene, its coding region was cloned
into S. cerevisiae expression vectors, and the resulting plas-
mids were transformed into sky1 or SKY1 cells. When the
Fig. 1. Cisplatin sensitivity of untransformed yeast sky1 versus SKY1
cells and SKY1-transformed cells. A, cisplatin sensitivity profiles of S.
cerevisiae MGSC131 SKY1 cells (), isogenic MGSC-sky1 cells (F),
MGSC-sky1 cells transformed with pYCTEF (f), and MGSC-sky1 cells
transformed with pYCTEF-SKY1 (E). pYCTEF is a low-copy yeast ex-
pression vector harboring the constitutive translation elongation factor
1 promoter. Percentage survival (colony formation) at each concentra-
tion of cisplatin is expressed relative to untreated control cells (100%).
Means of three independent experiments performed in triplicate are
shown, with bars representing S.D. Bars are sometimes masked by the
data point symbols. The data shown have been presented previously
(Schenk et al., 2001). B, yeast transformants carrying high-copy plasmids
were tested for their relative ability to grow on cisplatin by streaking onto
selective medium plates containing the indicated drug concentrations. 1,
S. cerevisiae MGSC-sky1 cells transformed with pEG202; 2, MGSC-
sky1 cells transformed with pEG202-SKY1; 3, empty vector-trans-
formed MGSC131 SKY1 cells. pEG202 is a high-copy yeast expression
vector harboring the constitutive alcohol dehydrogenase promoter. C-D,
cisplatin sensitivity profiles of S. cerevisiae rad52 SKY1 cells (C, ‚),
isogenic rad52 sky1 cells (C, Œ), W303-1B-derived MGSC186 SKY1
cells (D, ƒ) and isogenic W303-sky1 cells (D, ). Percentage survival
(colony formation) at each concentration of cisplatin is expressed relative
to untreated control cells (100%). Means of typical experiments per-
formed in triplicate are shown, with bars representing S.D..
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low-copy plasmid pYCTEF-SKY1 (with SKY1 under the con-
stitutive translation elongation factor 1 promoter) was
transformed into MGSC-sky1 cells, the cisplatin-resistant
phenotype was fully complemented. The cells became as sen-
sitive to cisplatin as the original MGSC131 SKY1 strain,
while transformation with pYCTEF alone did not reduce the
resistance of the sky1 cells at all (Fig. 1A). Overexpression
from the high-copy plasmid pEG202-SKY1 (SKY1 under the
constitutive alcohol dehydrogenase promoter) also showed
full complementation of the cisplatin resistance phenotype,
whereas cells transformed with the empty vector alone were
still resistant (Fig. 1B). Notably, the pEG202-SKY1 trans-
formants were markedly more sensitive to cisplatin than
empty vector-transformed SKY1 cells (Fig. 1B). These data
strongly affirm that the cisplatin resistance, which was orig-
inally observed in the transposon-derived strains, was linked
to disruption of the SKY1 gene, and suggest that overexpres-
sion of SKY1 makes yeast cells hypersensitive to cisplatin.
To rule out the possibility that NER deficiency would be
functionally involved in the cisplatin resistance phenotype of
sky1 cells, we used two independent, NER-proficient back-
grounds. Because rad52 cells are about as sensitive to cis-
platin as rad4 cells (McA’Nulty and Lippard, 1996), the
RAD52 gene involved in recombinational repair was first
disrupted from NER-proficient sky1 cells by one-step gene
replacement. The cisplatin sensitivity profile of the resulting
rad52 sky1 mutants was then determined, compared with
that of rad52 SKY1 cells (Fig. 1C). S. cerevisiae rad52
sky1 cells were 3- to 4-fold more cisplatin-resistant than
rad52 SKY1 cells, which is similar to the effect of SKY1
disruption in rad4 backgrounds. Second, the SKY1 gene
was disrupted in NER- and recombinational repair-proficient
wild-type cells, which display a relatively flat dose-response
curve compared with cisplatin. Strain W303-sky1 was gen-
erated by one-step gene replacement, and monitored for cis-
platin resistance. Replacement of SKY1 by a disrupted copy
also made these wild-type cells resistant to cisplatin (Fig.
1D), with a striking similarity in resistance level: S. cerevi-
siae W303-sky1 cells were 3- to 4-fold cisplatin-resistant
compared with isogenic MGSC186 SKY1 cells. Taken to-
gether, these data show that SKY1 disruption-derived cispla-
tin resistance is independent of the rad4 genotype. Notably,
irrespective of their backgrounds, all replacement-derived
sky1 strains displayed normal growth characteristics (data
not shown).
Cross-Resistance of Yeast Cells Containing a Dis-
rupted SKY1 Gene. To determine the specificity of the
resistance phenotype and to learn more about the underlying
mechanisms, we assayed sky1 mutants for cross-resistance
to other cytotoxic agents. Colony formation assays were per-
formed with a range of different classes of chemicals (mostly
anticancer drugs), including cisplatin analogs (carboplatin
and oxaliplatin), heavy metals (cadmium chloride and so-
dium arsenite), classical alkylating agents [busulfan, strep-
tozotocin, N-nitroso-N-methylurea (NMU), and procarba-
zine], a bioreductive alkylating agent (mitomycin C),
antimetabolites (6-mercaptopurine and 5-fluorouracil), a to-
poisomerase I inhibitor (camptothecin), topoisomerase II in-
hibitors (doxorubicin, daunorubicin, and etoposide), and an
antibiotic (oligomycin). In addition, possible cross-resistance
to DNA damaging agents (ionizing radiation and UV light)
was monitored.
Disruption of SKY1 did not only confer resistance to cis-
platin, but also to the cisplatin analog carboplatin (Table 1;
Fig. 2). Furthermore, the inactivation of SKY1 conferred
resistance to the anthracycline drugs doxorubicin and dauno-
rubicin (Table 1; Fig. 2), which are thought to inhibit topo-
isomerase II through DNA intercalation (Pratt et al., 1994).
However, sensitivity toward the cisplatin analog oxaliplatin
and another topoisomerase II inhibitor, etoposide, was not
changed. In addition, we did not observe any change in sen-
sitivity toward sodium arsenite, busulfan, streptozotocin,
NMU, procarbazine, mitomycin C, 6-mercaptopurine, camp-
tothecin, oligomycin, ionizing radiation, or UV light. Surpris-
ingly, sky1 mutants were hypersensitive toward cadmium
chloride and 5-fluorouracil. In Fig. 2, representative exam-
ples of compound concentration versus colony formation are
given (i.e., survival curves for carboplatin, oxaliplatin, doxo-
rubicin, cadmium chloride, 5-fluorouracil, and NMU are
shown).
In eukaryotic cells, including yeast, resistance to anthra-
cyclines might be caused by emergence of a multidrug resis-
tance (MDR)/pleiotropic drug resistance (PDR) phenotype
(Kolaczowska and Goffeau, 1999), characterized by overex-
pression of a drug efflux pump the activity of which can be
blocked by a variety of modulators, including verapamil
(Hogue et al., 1999). To rule out the possible involvement of
an MDR/PDR phenotype in sky1 yeast, the cells were incu-
bated with a concentration range of doxorubicin in the pres-
ence of a fixed dose of verapamil (1.7 mM) that had previ-
ously been shown to be effective in blocking an MDR
phenotype in yeast (Hogue et al., 1999), and growth was
determined in a semiquantitative spot assay. The dose of
verapamil used did not affect cell growth by itself, neither did
it have any effect on doxorubicin resistance in sky1 yeast
cells (Fig. 3).
Platinum Accumulation and DNA Platination are
Unaffected in Yeast sky1Mutants. Recently, it was dem-
onstrated that disruption of the SKY1 gene results in a
dramatically reduced uptake of the polyamines spermine,
spermidine, and their precursor, putrescine, corresponding
with tolerance to toxic levels of spermine (Erez and Kahana,
2001). To determine whether, by analogy, the cisplatin resis-
tance phenotype of sky1 mutant cells was linked to im-
TABLE 1
Effect of SKY1 disruption on yeast sensitivity to cytotoxic agents
Sensitivity was monitored by colony formation assays in S. cerevisiae sky1 cells (i.e.,
cells from which the SKY1 gene had been disrupted) versus isogenic SKY1 cells. For
each agent, these assays were performed at least three times, and consistent results
were obtained each time. Resistance or hypersensitivity factors were calculated from
the IC50 values as estimated from Figs. 1 and 2. Different classes of chemicals are
indicated by footnotes.
Resistance Cisplatina (4-fold) Carboplatina (2-fold)
Doxorubicinb (2-fold) Daunorubicinb
Hypersensitivity Cadmium chloridec 5-Fluorouracild
(5-fold) (3-fold)
No change Oxaliplatina Etoposideb
Sodium arsenitec 6-Mercaptopurined
Busulfane Streptozotocine
NMUe Procarbazinee
Mitomycin Ce Camptothecin
Oligomycin
Ionizing radiation UV light
a Platinum analogs.
b Topoisomerase II inhibitors.
c Heavy metals.
d Antimetabolites.
e Alkylating agents.
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paired drug accumulation or platination, cellular platinum
content and platinum-DNA adduct formation were moni-
tored by AAS (Burger et al., 2000) and a postlabeling assay
(Pluim et al., 1999), respectively. A clear dose-effect relation-
ship between cisplatin exposure and both accumulation and
platination was found. However, S. cerevisiae sky1 cells did
not seem to display decreased platinum accumulation com-
pared with SKY1 cells (data not shown). Furthermore, S.
cerevisiae MGSC-sky1 cells did not show a decrease in pla-
tination compared with the original MGSC131 SKY1 strain
(Fig. 4). Therefore, the observed cisplatin resistance can
probably not be attributed to major alterations in specific cell
wall components, changes in plasma membrane permeabil-
ity, impaired nuclear drug import or reduced formation of
cytotoxic intrastrand platinum-DNA adducts (Pratt et al.,
1994; Johnson et al., 1998).
Doxorubicin Accumulation Is Unaffected in Yeast
sky1 Mutants. To reveal whether the doxorubicin resis-
tance phenotype of S. cerevisiae sky1 mutants was associ-
ated with impaired drug accumulation, cellular doxorubicin
content was determined by HPLC (de Bruijn et al., 1999).
Analogous to the platinum accumulation and platination ex-
periments, a clear dose-effect relationship between doxoru-
bicin exposure and accumulation was found. Yet, likewise,
MGSC-sky1 cells did not show a decrease in cellular doxo-
rubicin content compared with the original SKY1 strain
(Fig. 5); neither did we see any effect of verapamil on doxo-
rubicin accumulation in sky1 or SKY1 cells (data not
shown). So, in parallel to the situation for cisplatin, the
observed doxorubicin resistance is most probably unrelated
to decreased drug import or increased drug export.
Yeast sky1 Mutants Display a Mutator Phenotype.
As changes in intracellular drug accumulation do not seem to
play a role in the observed cisplatin and doxorubicin resis-
tance phenotype, alternative mechanisms might explain our
data. MMR deficiencies have previously been shown to cor-
respond to resistance to both cisplatin and carboplatin, but
not oxaliplatin, in cultured colon, endometrial, and ovarian
cancer cells (Fink et al., 1996; Vaisman et al., 1998). Further-
more, it has been demonstrated that cisplatin and doxorubi-
cin resistance are associated with MMR deficiency in an
ovarian tumor cell line (Drummond et al., 1996), and that
Fig. 2. Sensitivity to cytotoxic compounds of yeast sky1 versus SKY1
cells. A to F, sensitivity profiles of S. cerevisiae MGSC131 SKY1 cells ()
and isogenic MGSC-sky1 cells (F) toward the agent indicated on the
x-axis. Percentage survival (colony formation) at each compound concen-
tration is expressed relative to untreated control cells (100%). Means of
typical experiments performed in triplicate are shown, with bars repre-
senting S.D.. Bars are sometimes masked by the data point symbols.
Please note that the ordinates of the graphs are in different ranges.
Fig. 3. Effect of MDR modulator verapamil on doxorubicin sensitivity of
S. cerevisiae sky1 versus SKY1 cells. Yeast MGSC131 SKY1 and
isogenic MGSC-sky1 cells were tested for their relative ability to grow
on selective medium plates containing the indicated doxorubicin concen-
trations (0, 60, 120 or 240 g/ml) in the absence (, top row) or presence
(, bottom row) of 1.7 mM verapamil by spotting aliquots of 105 (a), 104
(b), 103 (c) and 102 (d) cells, and incubating at 30°C for 4 days.
Fig. 4. DNA platination in yeast sky1 versus SKY1 cells. S. cerevisiae
MGSC131 SKY1 cells () and isogenic MGSC-sky1 cells (F) were
incubated with various concentrations of cisplatin, and DNA platination
was measured by postlabeling. Data from a typical experiment (of three
performed in duplicate) are shown. The ApG adduct levels, which were
much lower than the GpG levels shown here, did not clearly differ
between the yeast strains either.
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loss of MMR renders yeast cells resistant to cisplatin, carbo-
platin, and doxorubicin (Durant et al., 1999). It could thus be
proposed that reduced MMR might contribute to drug resis-
tance in the sky1 yeast cells.
Because MMR defects are generally accompanied by a so-
called mutator phenotype (Branch et al., 1995), we explored
whether sky1 cells displayed an enhanced rate of spontane-
ous mutation compared with SKY1-proficient cells. The rate
of forward mutation at the URA3 locus was determined for
MGSC-sky1 cells and isogenic MGSC284 SKY1 cells. As
shown in Fig. 6, there was a 2.4-fold increase of the mutation
rate per replication in the sky1 strain (rate  7.4  10-7),
compared with the SKY1 strain (rate  3.1  10-7). This
indicates that, indeed, disruption of the S. cerevisiae SKY1
gene induces a mutator phenotype.
Discussion
We have used the budding yeast Saccharomyces cerevisiae
to search for novel genes whose functional abrogation confers
cellular resistance to the commonly applied anticancer agent
cisplatin, and found that a 4-fold cisplatin resistance was
linked to disruption of the SKY1 gene (Schenk et al., 2001).
Because constitutive expression of SKY1 from a high-copy
vector made sky1 yeast cells markedly more sensitive to
cisplatin compared with a SKY1 control strain, SKY1 may
be a cisplatin sensitivity gene that is actively involved in the
pathway of cisplatin-induced cell kill. One of the physiologi-
cal functions of Sky1p could actually be to down-regulate
RNA processing (leading to growth inhibition or even cell
death) upon its translocation from the cytoplasm to the nu-
cleus in response to specific events (Siebel et al., 1999), in-
cluding treatment with antiproliferative drugs.
In cross-resistance studies, we exclusively found resistance
of sky1 yeast cells to cisplatin, carboplatin, and the anthra-
cyclines doxorubicin and daunorubicin. Apparently, the re-
sistance is not associated with covalent DNA binding per se,
because sky1 cells did not show cross-resistance to other
alkylators, such as the alkane sulfonate busulfan, the nitro-
soureas streptozotocin and NMU, and the methylating agent
procarbazine. The anthracyclines doxorubicin and daunoru-
bicin (drugs that interact with DNA by intercalation), as well
as the epipodophyllotoxin etoposide, are thought to have the
enzyme topoisomerase II as their main intracellular target
(Pratt et al., 1994). The lack of cross-resistance to etoposide
strongly suggests that topoisomerase II is not involved in the
anthracycline-resistant phenotype of sky1 cells. Therefore,
another consequence of DNA intercalation might be of vital
importance here. Another set of drugs that we compared for
changes in the capacity to inhibit yeast colony formation was
the hypoxanthine analog and purine antagonist 6-mercapto-
purine versus the pyrimidine antagonist 5-fluorouracil. Al-
though no change in the response to 6-mercaptopurine was
observed, hypersensitivity to 5-fluorouracil was evident in
sky1 mutants.
The doxorubicin resistance phenotype of yeast sky1 mu-
tant cells does not seem to be linked to impaired doxorubicin
accumulation. Therefore, a role for the S. cerevisiae PDR
network, which comprises the functional P-glycoprotein ho-
molog Pdr5p and the MRP homolog Yor1p (Kolaczowska and
Goffeau, 1999), seems unlikely. Our finding that the sensi-
tivity of sky1 cells toward oligomycin was unaltered, is in
line with this, as overexpression of Yor1p has previously been
associated with resistance to this drug (Katzmann et al.,
1995). The yeast activator protein-1–like factor network com-
prising the Ycf1p detoxification pump for glutathione conju-
gates, which is essential to cadmium tolerance (Kolaczowska
and Goffeau, 1999), does probably not play a role in the
observed cisplatin or doxorubicin resistance either, because
activation of this pump would also lead to reduced drug
accumulation. Yet, this network may be affected in sky1
cells, rendering them hypersensitive to cadmium chloride.
Although heavy metals are generally thought to share cellu-
lar pathways modulating their toxicity, it has previously
been shown that cisplatin-resistant cells are not necessarily
cross-resistant to cadmium, and, vice versa, cadmium-hyper-
sensitive cells are not automatically hypersensitive to cispla-
Fig. 5. Doxorubicin accumulation in yeast sky1 versus SKY1 cells. S.
cerevisiae MGSC131 SKY1 cells () and isogenic MGSC-sky1 cells (F)
were incubated with various concentrations of doxorubicin, and cellular
drug content was measured by HPLC. Means of a typical experiment
performed in duplicate are shown, with bars representing S.D. Bars are
sometimes masked by the data point symbols.
Fig. 6. Spontaneous mutation rates in yeast sky1 versus SKY1 cells.
Mutant frequencies at the URA3 locus were determined in 15 individual
parallel cultures of either S. cerevisiae MGSC284 SKY1 cells (o) or
isogenic MGSC-sky1 cells (f). For each strain, bars are grouped accord-
ing to the data obtained, with frequencies increasing from left to right.
The mutation rates per replication were calculated from the median
mutant frequencies indicated by vertical arrows.
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tin. In parallel to the findings presented here, a cisplatin-
resistant murine leukemia cell line was found to be
hypersensitive to cadmium (Farnworth et al., 1990). Con-
versely, a cadmium-hypersensitive Schizosaccharomyces
pombe mutant was demonstrated to be as tolerant to cispla-
tin as the corresponding wild-type strain (Perego et al.,
1997). Interestingly, Erez and Kahana (2001) have recently
shown that S. cerevisiae sky1 cells exhibit increased toler-
ance to high concentrations of some inorganic ions (0.2 M
lithium chloride or 1.2 M sodium chloride), but increased
sensitivity to osmotic shock at 1.5 M potassium chloride or
1.5 M sorbitol.
Summarizing our present cytotoxicity data, obtained com-
paring yeast sky1 cells to isogenic SKY1 cells, the most
striking pattern was that of resistance to cisplatin, carbopla-
tin and doxorubicin, unaltered sensitivity to oxaliplatin, and
hypersensitivity to 5-fluorouracil. As mentioned earlier, loss
of MMR has previously been associated with resistance to
cisplatin, carboplatin and doxorubicin, but not oxaliplatin, in
mammalian cells as well as in yeast (Drummond et al., 1996;
Fink et al., 1996; Vaisman et al., 1998; Durant et al., 1999).
In drug-sensitive cells, binding of MMR proteins to cisplatin-
or carboplatin-derived DNA adducts may directly or indi-
rectly activate signal transduction pathways involved in cell
kill. MMR proteins seem to function as detectors of platinum-
DNA 1,2-intrastrand GpG cross-links induced by cisplatin
and carboplatin (Duckett et al., 1996; Fink et al., 1996) and
probably propagate signals that contribute to activation of
programmed cell death (Toft et al., 1999). Recently, it has
been suggested that doxorubicin inhibits the correction of
DNA mismatches in vitro by preventing MutS-mediated
mismatch recognition through reversible DNA intercalation,
which might at last link doxorubicin to MMR-dependent drug
resistance mechanistically (Larson and Drummond, 2001).
Interestingly, recent findings by Hemminki et al. (2000) im-
ply that loss of MMR might also contribute to 5-fluorouracil
hypersensitivity. It was shown that, after 5-fluorouracil-
based therapy, the prognosis of colorectal cancers character-
ized by microsatellite instability (a hallmark of an MMR
defect) is significantly better than that of patients without
microsatellite instability, suggesting that MMR-deficient tu-
mors could be hypersensitive to 5-fluorouracil (Hemminki et
al., 2000). Given our drug sensitivity data and the finding
that S. cerevisiae sky1 cells also display a mutator pheno-
type (another hallmark of an MMR defect), the MMR system
may thus be impaired in these yeast cells.
In human cancer cells, MMR deficiency has also been as-
sociated with tolerance to DNA methylation damage inflicted
by agents such as NMU, N-methyl-N-nitro-N-nitrosoguani-
dine, temozolomide, and procarbazine (Branch et al., 1995;
Friedman et al., 1997). In S. cerevisiae, however, it has been
shown that mutations in MMR genes (except MSH5) do not
render cells more tolerant to methylation-induced kill (Bawa
and Xiao, 1997), in line with our present data. This hints at
alternative mechanisms involved in methylation-induced
killing, and indicates that there may be a discrepancy be-
tween yeast and mammalian cells with respect to tolerance to
methylating agents.
Durant et al. (1999) recently demonstrated that, whereas
disruption of several MMR genes, including MLH1, MLH2,
and MSH2, led to cisplatin, carboplatin and doxorubicin re-
sistance in S. cerevisiae RAD52 cells, inactivation of MLH1,
MLH2, or MSH2 in a yeast rad52 strain did not result in
cisplatin or carboplatin resistance. Because we show that
rad52 sky1 cells are 3- to 4-fold cisplatin-resistant com-
pared with rad52 SKY1 cells (which is a resistance level
similar to that observed in a rad4 or wild-type background),
the cisplatin resistance observed in our present study can
probably not be straightforwardly explained by deficiencies
in MMR proteins Mlh1p, Mlh2p, or Msh2p. Nevertheless,
deregulation of other MMR components, such as Msh3p or
Msh6p, may have an effect on drug sensitivity in S. cerevisiae
rad52 backgrounds and could thus be involved in the cis-
platin-resistant phenotype of sky1 cells.
However, cisplatin resistance in combination with a muta-
tor phenotype might, for instance, still (partly) result from
up-regulation of functional homologs to DNA polymerase ,
which is involved in base excision repair. It has recently been
demonstrated that elevated activity of DNA polymerase ,
corresponding to enhanced translesion synthesis across pla-
tinated DNA cross-links, occurs in cisplatin-resistant human
ovarian carcinoma cells; at the same time, DNA polymerase
 is one of the most inaccurate DNA synthesizing enzymes
conferring genetic instability when up-regulated in such cells
(Bergoglio et al., 2001). Alternatively, an up-regulation of the
Rev3p (DNA polymerase ) pathway involved in error-prone
damage tolerance could possibly (partly) underlie both cis-
platin resistance and the mutator phenotype of sky1 cells,
as S. cerevisiae rev3 cells are hypersensitive to cisplatin
(Simon et al., 2000) and possess an antimutator phenotype
(Roche et al., 1994). This alternative hypothesis may, how-
ever, not account for other aspects of the sky1 phenotype,
for instance doxorubicin resistance, because REV3 disruption
seems to cause doxorubicin resistance instead of hypersensi-
tivity (Simon et al., 2000).
Anyhow, the exact pathway through which Sky1p contrib-
utes to the cytotoxic action of cisplatin, carboplatin, and
doxorubicin in yeast remains to be resolved in more detail.
Heterologous yeast complementation experiments, employ-
ing wild-type versus kinase dominant-negative human
SRPK1, strongly suggest that the protein kinase function of
SR-protein–specific kinases is essential to their involvement
in the cytotoxicity of cisplatin (Schenk et al., 2001). Although
Sky1p may fulfill its role in increasing sensitivity to lithium
chloride via the protein phosphatase Ppz1p comprising SR
segments at its NH2-terminal region, it has not yet been
established whether Ppz1p is indeed phosphorylated by
Sky1p (Erez and Kahana, 2001). The S. cerevisiae SR-protein
Npl3p (nuclear protein localization) is phosphorylated by
Sky1p both in vitro and in vivo (Siebel et al., 1999), and
shuttles between the cytoplasm and the nucleus (where it
resides primarily at steady state) to deliver proteins and/or
mRNA. Phosphorylation of Npl3p and mammalian SR-pro-
teins modulates protein-protein and protein-RNA interac-
tions. In sky1 cells, Npl3p is mislocalized to the cytoplasm
because of impaired interaction between Npl3p and its nu-
clear import receptor and, thus, decreased nuclear import
(Yun and Fu, 2000). This might implicate that Npl3p-medi-
ated nuclear import of (accessory) components involved in
drug-induced cell kill would also be decreased in yeast sky1
cells, leading to deregulation of processes influencing cyto-
toxicity. Of course, Sky1p may be a key player in other
pathways determining drug sensitivity as well and, there-
fore, additional mechanisms may contribute to the resistance
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and hypersensitivity phenotype observed in S. cerevisiae
sky1 cells.
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